Cardiff Oncology (CRDF) Projected to Release Quarterly Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Cardiff Oncology to post earnings of ($0.1380) per share and revenue of $0.08 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.06 million. Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%. On average, analysts expect Cardiff Oncology to post ($0.60) EPS for the current fiscal year and ($0.56) EPS for the next fiscal year.

Cardiff Oncology Price Performance

NASDAQ CRDF opened at $0.86 on Wednesday. The business has a fifty day simple moving average of $1.08 and a 200 day simple moving average of $1.43. Cardiff Oncology has a 12 month low of $0.76 and a 12 month high of $3.31.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CRDF. HC Wainwright upgraded shares of Cardiff Oncology from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 15th. William Blair lowered shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of Cardiff Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Finally, Weiss Ratings cut shares of Cardiff Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 23rd. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cardiff Oncology presently has an average rating of “Hold” and a consensus price target of $7.50.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division.

Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer.